FILTERED RESULTS
FILTERS
Ads Top
DARK MODE
CHART
    Filters
      Symbols
      Sentiment
      Impact
      Search
      FILTERED RESULTS

        

      Upgrade your plan

      Halozyme Therapeutics Enters Exclusive Collaboration with Vertex Pharmaceuticals

      Halozyme Therapeutics, Inc. (NASDAQ: HALO) has announced a significant collaboration with Vertex Pharmaceuticals Incorporated. On April 7, the company revealed that its subsidiary, Halozyme Hypercon, Inc., has entered into a global exclusive collaboration and license agreement with Vertex.

      Under this agreement, Vertex has obtained a license for Halozyme's Hypercon™ technology. This partnership is expected to enhance Vertex's capabilities in developing innovative therapies, leveraging Halozyme's advanced technology in the biotech sector. The collaboration highlights Halozyme's position in the market and its potential for growth as a key player in the biotechnology industry.

      © 2026 KLEA News. All Rights Reserved. This article is provided for informational purposes only. It is not offered or intended to be used as legal, tax, investment, financial, or other advice.

      Source: KLEA News

      .

      Terra Founder Do Kwon Sentenced to 15 Years in Prison for Fraud